Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

Christos Stafylidis; Dimitra Vlachopoulou; Christina-Nefeli Kontandreopoulou; Panagiotis Τ Diamantopoulos

doi:10.3390/jcm13041082

Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

J Clin Med. 2024 Feb 14;13(4):1082. doi: 10.3390/jcm13041082.

Authors

Christos Stafylidis¹, Dimitra Vlachopoulou¹, Christina-Nefeli Kontandreopoulou¹, Panagiotis Τ Diamantopoulos¹

Affiliation

¹ Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Abstract

Acute myeloid leukemia (AML) remains a challenging hematologic malignancy. The presence of TP53 mutations in AML poses a therapeutic challenge, considering that standard treatments face significant setbacks in achieving meaningful responses. There is a pressing need for the development of innovative treatment modalities to overcome resistance to conventional treatments attributable to the unique biology of TP53-mutated (TP53^mut) AML. This review underscores the role of TP53 mutations in AML, examines the current landscape of treatment options, and highlights novel therapeutic approaches, including targeted therapies, combination regimens, and emerging immunotherapies, as well as agents being explored in preclinical studies according to their potential to address the unique hurdles posed by TP53^mut AML.

Keywords: AML immunotherapies; TP53 mutations; TP53-mutated acute myeloid leukemia; acute myeloid leukemia; novel targeted AML therapies.

Publication types

Review

Grants and funding

This research received no external funding.